N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,785 Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
Posterior Capsule Opacification
Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
N/A N=2,280 Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
Aphakia · Presbyopia · Astigmatism
Primary: Rate of Eyes With Post-Surgical Intraocular Inflammation - By Eye - Cohort 2 — 5.6; 4.5 event rate per 1000 implants
N/A N=50 Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Cataract · Retinal Edema · Inflammation
Primary: Treatment of Inflammation Associated With Cataract Surgery — 0.01; 0.01 units on a scale
N/A N=100 Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Capsule Opacification · Pseudophakia · Cataract
Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)
N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
N/A N=410 Post-Market Evaluation of the EVO ICL
Myopia · Myopic Astigmatism
Primary: Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 30 mmHg — 15 Eyes
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
Phase 3 N=178 Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Cataract
Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
N/A N=49 Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Pseudophakia · Inflammation
Primary: Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract…
Phase 4 N=132 Presbyopia-Correcting Intraocular Lenses (IOLs)
Cataract
Primary: Best Corrected Visual Acuity — -0.075; -0.080; -0.081; 0.227 logMAR
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 4 N=20 Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
Keratoconus, Unstable · Collagen Crosslinking · Postoperative Pain
Primary: Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3…
Phase 3 N=416 Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=0.0001
N/A N=193 Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
Aphakia
Primary: Percentage of Subjects Not Bothered at All by Halos (QUVID Question 2.3) — 88.7; 58.1; 58.6 percentage of subjects
N/A N=162 Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).
Cataract
Primary: Posterior Capsule Opacification (PCO) — 0.18; 0.15 Units on a scale
Phase 4 N=28 Intraoperative Floppy Iris Syndrome
Cataract · Floppy Iris Syndrome
Primary: Corneal Endothelial Cell Loss — 9.85; -3.68 Percent change
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
Phase 4 N=93 Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction
Cataract
Primary: Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree) — 1.612; 1.582; 1.527; 1.658 log contrast sensitivity units
N/A N=109 Clinical Investigation of Corneal Incision Size After Intraocular Lens (IOL) Implantation
Cataracts
Primary: Mean Corneal Incision Size After IOL Implantation (UltraSert, iTec, and iSert) — 2.35; 2.47; 2.54 mm
N/A N=218 Clinical Investigation of the Next Generation Intraocular Lens
Cataract
Primary: Monocular, Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeter (cm) — 0.053; 0.370 logMAR — p=< 0.0001
Phase 4 N=78 Evaluation of 3 Intraocular Lenses Following Lens Extraction
Cataract
Primary: Mesopic Monocular Contrast Sensitivity Without Glare 1.5 and 3 Cycles/Degree — 1.494; 1.576; 1.410; 1.613 log contrast sensitivity units
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 4 N=75 Clinical Evaluation of a New Aspheric Intraocular Lens.
Cataract
Primary: Low Contrast Best Corrected Visual Acuity Following Cataract Surgery — 0.22; 0.24 LogMAR
Phase 3 N=269 Clinical Evaluation of a 1-Piece Intraocular Lens
Cataract
Primary: Mean Percent Reduction in Cylinder — 32; 75; 76. percentage of reduction in cylinder — p=<0.0001
Phase 3 N=107 Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
Cataract
Primary: Anterior Chamber Inflammation — .913; .783 grade of anterior chamber cells